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treat these patients and manage symptoms associated with
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Complete  remission  of nephro
with renal  amyloidosis  due  to
Remisión  completa  de  síndrome  n
renal  por  ﬁebre  mediterránea  fam
Dear Editor,
Chronic kidney disease due to AA amyloidosis is one of th
main complications of Familial Mediterranean Fever (FMF).
In 2009, in the journal Nefrología,  we presented the case of 
38-year-old woman of Armenian origin with severe nephroti
syndrome due to AA amyloidosis as a form of onset of FM
(with heterozygous M680I and M694V mutations in the MEFV
gene). Given the severity of her proteinuria at diagnosis
deterioration in renal function and intolerance to antiprotein
uric drugs, we started treatment with colchicine, at doses o
0.5 mg/8 h/day, and inﬂiximab, at doses of 5 mg/kg IV at base
line, at 2 weeks and subsequently every 2 months. In th
clinical follow-up performed in the ﬁrst year of treatment t
evaluate her response to this, we reported partial remission
clinical improvement and improvement in renal function, bu
2with persistent nephrotic proteinuria.
In this report we  describe her mid-term clinical course. In
the following 6 years, the patient has remained asymptomatic
with no new episodes of hydropic decompensation or hos-
pital admissions. Table 1 shows the clinical course of both
her laboratory values and the treatment followed. Starting
from the second year of treatment, colchicine was sustained
 Please cite this article as: Heras M, Saiz A, Fernández-Reyes MJ, Mo
síndrome nefrótico en mujer con amiloidosis renal por ﬁebre mediterc  syndrome  in a woman
milial  Mediterranean  Fever
rótico  en  mujer  con  amiloidosis
r
continuously at doses of 1 mg/day. Given that her proteinuria
progressively decreased, inﬂiximab doses were increasingly
spaced out, to intervals of 4–6 months, and this treatment wa
permanently suspended in 2011.
As a result of combination therapy with colchicine and
inﬂiximab, in the acute phase of diagnosis of AA amyloidosi
due to FMF,  clinical improvement and improvement in rena
function were achieved, but nephrotic proteinuria persisted
Subsequent follow-up required us to modify our initial conclu
sions: her clinical improvement was maintained, without any
new hydropic decompensation, in the context of resolution o
her proteinuria.
Treatment with colchicine is effective in preventing amy
loidosis in Armenian patients with FMF.3 In cases of colchicine
resistance or intolerance, anti-TNF agents may be effective tolina A, Astrid Rodríguez M, Callejas R. Remisión completa de
ránea familiar. Nefrologia. 2016;36:331–332.
FMF. In our case, given the initial severity of nephrotic
syndrome, together with the ﬁndings of AA amyloid in the
renal parenchyma and the M694V mutation associated with
the most serious cases, combination therapy was decided
upon, with a partial response in the ﬁrst year and subse-
quently a complete response sustained over time. Perhaps
this combination treatment, as it prevented the onset of
332  n e f r o l o g i a. 2 0 1 6;3 6(3):318–332
Table 1 – Clinical course of laboratory values and treatments used.
PCr
(mg/dl)
COLCHICINE
INFLIXIMAB
PCr:  plasma creatinine; Chol.:  cholesterol; TGs: tr iglycerides;  CrCl:  creatinine clearance.
Chol.
(mg/dl)
TGs (mg/dl)
Albumin
(g/dl)
Proteinuria
(g/24 h)
CrCl
(ml/min)
1.9 1.6 2.9 3.7 3.8 .
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.
.
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new autoinﬂammatory episodes associated with FMF, would
prevent more  amyloid from being deposited in the renal tis-
sue and, furthermore, progressive regression of the amyloid
accumulated. In this case, we cannot conﬁrm this, lacking
new histology. However, the signs and symptoms may sug-
gest it, as resolution of her proteinuria was achieved. In
this regard Kutlugün et al. also reported in the literature
2 cases of complete remission of nephrotic syndrome with
colchicine 1.5 mg/day, sustained for a period of close to 30
ye
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r  
1.
2.
3.
Mediterranean fever with colchicine: a case–control study in
Armenia. Med Princ Pract. 2009;18:441–6.
4. Erten S, Erten SF, Altunoglu A. Successful treatment with
anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a
patient with Familial Mediterranean fever (FMF) resistant to
colchicines: anti-TNF drugs and FMF. Rheumatol Int.
2012;32:1095–7.
5. Ozgocmen S, Akgul O. Anti-TNF agents in Familial
Mediterranean fever: report of three cases of review of the
literature. Mod Rheumatol. 2011;21:684–90.
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In conclusion, the main kidney complication (chronic kid-
ey disease) associated with AA amyloidosis due to FMF
uld be prevented through a resolution of proteinuria, which
uld be achieved with initial intensive combination therapy
olchicine + anti-TNF agent) and subsequent maintenance
ith colchicine.
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